NASDAQ:SOLYSoliton Stock Price, Forecast & News

Soliton's stock was trading at $10.66 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SOLY shares have decreased by 23.5% and is now trading at $8.15. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soliton in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Soliton.

Soliton is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Soliton.

Soliton Inc (NASDAQ:SOLY) released its quarterly earnings data on Thursday, May, 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.25) by $0.06. View Soliton's earnings history.

2 analysts have issued 1 year price objectives for Soliton's stock. Their forecasts range from $16.00 to $22.00. On average, they anticipate Soliton's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 133.1% from the stock's current price. View analysts' price targets for Soliton.

Headlines about SOLY stock have been trending negative this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Soliton earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Soliton.

Soliton saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 1,410,000 shares, an increase of 7.6% from the June 15th total of 1,310,000 shares. Based on an average daily volume of 153,300 shares, the short-interest ratio is currently 9.2 days. Approximately 25.6% of the shares of the company are sold short. View Soliton's Current Options Chain.

Some companies that are related to Soliton include Anika Therapeutics (ANIK), LeMaitre Vascular (LMAT), Co-Diagnostics (CODX), Intersect ENT (XENT), SI-Bone (SIBN), Antares Pharma (ATRS), Repro Med Systems (KRMD), AngioDynamics (ANGO), Cytosorbents (CTSO), Repro-Med Systems (REPR), Utah Medical Products (UTMD), Alphatec (ATEC), Iradimed (IRMD), SeaSpine (SPNE) and Liquidia Technologies (LQDA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Soliton investors own include Cronos Group (CRON), Canopy Growth (CGC), NVIDIA (NVDA), Aurora Cannabis (ACB), Tesla (TSLA), Innovative Industrial Properties (IIPR), Micron Technology (MU), Square (SQ), AT&T (T) and Verizon Communications (VZ).

Soliton trades on the NASDAQ under the ticker symbol "SOLY."

Shares of SOLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SOLY stock can currently be purchased for approximately $8.15.

Soliton has a market capitalization of $138.33 million. The company earns $-13,750,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Soliton employs 7 workers across the globe.

The official website for Soliton is www.soliton.com.

Soliton's mailing address is 5304 ASHBROOK DRIVE, HOUSTON TX, 77081. The company can be reached via phone at 844-705-4866.